Timmerman sets the standard for excellence in biotech journalism.
There are a lot of writers commenting on the biopharmaceutical industry. Only a few really matter. Luke has proven himself to be one of them.
Luke has the rare ability to ask just the right questions to get underneath the standard “company line” and provide real insight.
Timmerman is always ahead of the game.
Biotech social media is easy to obtain, but is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.
Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read.
Luke Timmerman knows the deep secret of biotech: success requires technology plus people.
Luke has an uncanny ability to get to the heart of an issue, put it in a broader context and reveal what really matters. He makes the people and topics he covers come to life.
Timmerman Report has been fantastic for our students and postdocs here at MIT’s Koch Institute, based on overwhelmingly positive feedback. As many of our trainees move on to diverse positions within the biotech ecosystem, TR provides them with invaluable working knowledge, insight, and language beyond academia.
Luke speaks science, speaks medicine and speaks business. Oh, and he writes really well, too. Subscribing to TR is like having another analyst on the team.
TR is essential reading at EcoR1 Capital. Luke’s thoughts and insights not only report on the biotech sector but help shape it.
I enjoy the sharp writing and no-bullshit tone in Timmerman Report. This is journalism worth paying for.